Meriel Owen
Director @ Alzheimer's Drug Discovery Foundation
San Francisco Bay Area, United States
Meriel Owen is a Series B investor at Alzheimer's Drug Discovery Foundation in San Francisco Bay Area focused on Health Care and Neuroscience. Meriel Owen
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Meriel Owen invests in
Stages Meriel Owen invests in
Countries Meriel Owen invests in
Investment Focus
Industry
- Health Care 1 (100%)
- Neuroscience 1 (100%)
- Therapeutics 1 (100%)
- Pharmaceutical 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Neuro Therapia
|
NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain.Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and plan on studying NTRX-07 in humans in 2016. | $12.3M / Series B / Aug 06, 2024 |
Co-Investors
Cleveland Clinic
2 deals together
Brain Trust Accelerator Fund
1 deal together
CRUINT
1 deal together
Dolby Family Ventures
1 deal together
Foundation for a Better World
1 deal together
About Alzheimer's Drug Discovery Foundation
The Alzheimer’s Drug Discovery Foundation (ADDF) is the only public charity solely dedicated to finding effective drugs for Alzheimer’s disease. Our pioneering biomedical venture philanthropy approach allows us to invest in the most promising drug discovery and development programs around the world in both academic institutions andbiopharmaceutical companies. Since our founding in 1998, the ADDF has invested nearly $100 million to support over 500 programs across 18 countries.
Alzheimer's Drug Discovery Foundation Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Howard Fillit
Co-Founder and Chief Science Officer
|
|||
Leonard Lauder
Co-Chairman & Co-Founder
|
|||
Martin Tolar
Business Advisory Board & Scientific Review Board
|
|||
|
Meriel Owen
Director
|
|||
|
Ronald S. Lauder
Co-Chairman and Co-Founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Meriel Owen invest in?
Meriel Owen invests primarily in Health Care, Neuroscience and Therapeutics startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Meriel Owen last invest?
The most recent investment recorded for Meriel Owen closed in Aug 2024. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
